Literature DB >> 17074791

Inhibition of anthrax protective antigen outside and inside the cell.

Marina V Backer1, Vimal Patel, Brian T Jehning, Kevin P Claffey, Vladimir A Karginov, Joseph M Backer.   

Abstract

In the course of Bacillus anthracis infection, B. anthracis lethal factor (LF) and edema factor bind to a protective antigen (PA) associated with cellular receptors ANTXR1 (TEM8) or ANTXR2 (CMG2), followed by internalization of the complex via receptor-mediated endocytosis. A new group of potential antianthrax drugs, beta-cyclodextrins, has recently been described. A member of this group, per-6-(3-aminopropylthio)-beta-cyclodextrin (AmPrbetaCD), was shown to inhibit the toxicity of LF in vitro and in vivo. In order to determine which steps in lethal factor trafficking are inhibited by AmPrbetaCD, we developed two targeted fluorescent tracers based on LFn, a catalytically inactive fragment of LF: (i) LFn site specifically labeled with the fluorescent dye AlexaFluor-594 (LFn-Al), and (ii) LFn-decorated liposomes loaded with the fluorescent dye 8-hydroxypyrene-1,3,6-trisulfonic acid (LFn-Lip). Both tracers retained high affinity to PA/ANTXR complexes and were readily internalized via receptor-mediated endocytosis. Using fluorescent microscopy, we found that AmPrbetaCD inhibits receptor-mediated cell uptake but not the binding of LFn-Al to PA/ANTXR complexes, suggesting that AmPrbetaCD works outside the cell. Moreover, AmPrbetaCD and LFn-Al synergistically protect RAW 264.7 cells from PA-mediated LF toxicity, confirming that AmPrbetaCD did not affect the binding of LFn-Al to receptor-associated PA. In contrast, AmPrbetaCD did not inhibit PA-mediated internalization of LFn-Lip, suggesting that multiplexing of LFn on the liposomal surface overcomes the inhibiting effects of AmPrbetaCD. Notably, internalized LFn-Al and LFn-Lip protected cells that overexpressed anthrax receptor TEM8 from PA-induced, LF-independent toxicity, suggesting an independent mechanism for PA inhibition inside the cell. These data suggest the potential for the use of beta-cyclodextrins in combination with LFn-Lip loaded with antianthrax drugs against intracellular targets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074791      PMCID: PMC1797656          DOI: 10.1128/AAC.00983-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.

Authors:  B R Sellman; M Mourez; R J Collier
Journal:  Science       Date:  2001-04-27       Impact factor: 47.728

2.  Designing a polyvalent inhibitor of anthrax toxin.

Authors:  M Mourez; R S Kane; J Mogridge; S Metallo; P Deschatelets; B R Sellman; G M Whitesides; R J Collier
Journal:  Nat Biotechnol       Date:  2001-10       Impact factor: 54.908

3.  A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host.

Authors:  Anton Bom; Mark Bradley; Ken Cameron; John K Clark; Jan Van Egmond; Helen Feilden; Elizabeth J MacLean; Alan W Muir; Ronald Palin; David C Rees; Ming-Qiang Zhang
Journal:  Angew Chem Int Ed Engl       Date:  2002-01-18       Impact factor: 15.336

4.  Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes.

Authors:  Shigeru Miyata; Junzaburo Minami; Eiji Tamai; Osamu Matsushita; Seiko Shimamoto; Akinobu Okabe
Journal:  J Biol Chem       Date:  2002-08-12       Impact factor: 5.157

5.  Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins.

Authors:  M V Backer; J M Backer
Journal:  Bioconjug Chem       Date:  2001 Nov-Dec       Impact factor: 4.774

6.  Uncoupling of the cholera toxin-G(M1) ganglioside receptor complex from endocytosis, retrograde Golgi trafficking, and downstream signal transduction by depletion of membrane cholesterol.

Authors:  Anne A Wolf; Yukako Fujinaga; Wayne I Lencer
Journal:  J Biol Chem       Date:  2002-02-21       Impact factor: 5.157

7.  Identification of the cellular receptor for anthrax toxin.

Authors:  K A Bradley; J Mogridge; M Mourez; R J Collier; J A Young
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

8.  Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol.

Authors:  Lyne Labrecque; Isabelle Royal; David S Surprenant; Cam Patterson; Denis Gingras; Richard Béliveau
Journal:  Mol Biol Cell       Date:  2003-01       Impact factor: 4.138

9.  Initial steps of Shigella infection depend on the cholesterol/sphingolipid raft-mediated CD44-IpaB interaction.

Authors:  Frank Lafont; Guy Tran Van Nhieu; Kentaro Hanada; Philippe Sansonetti; F Gisou van der Goot
Journal:  EMBO J       Date:  2002-09-02       Impact factor: 11.598

10.  Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process.

Authors:  Laurence Abrami; Shihui Liu; Pierre Cosson; Stephen H Leppla; F Gisou van der Goot
Journal:  J Cell Biol       Date:  2003-01-27       Impact factor: 10.539

View more
  12 in total

1.  Imaging tumor endothelial marker 8 using an 18F-labeled peptide.

Authors:  Qimeng Quan; Min Yang; Haokao Gao; Lei Zhu; Xin Lin; Ning Guo; Guixiang Zhang; Henry S Eden; Gang Niu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-04       Impact factor: 9.236

Review 2.  Obstructing toxin pathways by targeted pore blockage.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Chem Rev       Date:  2012-10-11       Impact factor: 60.622

Review 3.  Cyclodextrin derivatives as anti-infectives.

Authors:  Vladimir A Karginov
Journal:  Curr Opin Pharmacol       Date:  2013-09-04       Impact factor: 5.547

Review 4.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

Review 5.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

6.  Blockage of anthrax PA63 pore by a multicharged high-affinity toxin inhibitor.

Authors:  Ekaterina M Nestorovich; Vladimir A Karginov; Alexander M Berezhkovskii; Sergey M Bezrukov
Journal:  Biophys J       Date:  2010-07-07       Impact factor: 4.033

7.  Symmetry requirements for effective blocking of pore-forming toxins: comparative study with alpha-, beta-, and gamma-cyclodextrin derivatives.

Authors:  Konstantina Yannakopoulou; Laszlo Jicsinszky; Crysie Aggelidou; Nikolaos Mourtzis; Tanisha M Robinson; Adiamseged Yohannes; Ekaterina M Nestorovich; Sergey M Bezrukov; Vladimir A Karginov
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

Review 8.  Anthrax toxin protective antigen--insights into molecular switching from prepore to pore.

Authors:  James G Bann
Journal:  Protein Sci       Date:  2012-01       Impact factor: 6.725

9.  Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells.

Authors:  Joseph M Backer; Arcadius V Krivoshein; Carl V Hamby; John Pizzonia; Kenneth S Gilbert; Yonaton S Ray; Harrison Brand; Adrienne W Paton; James C Paton; Marina V Backer
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

10.  Tailored ß-cyclodextrin blocks the translocation pores of binary exotoxins from C. botulinum and C. perfringens and protects cells from intoxication.

Authors:  Ekaterina M Nestorovich; Vladimir A Karginov; Michel R Popoff; Sergey M Bezrukov; Holger Barth
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.